1097-0215/asset/cover.gif?v=1&s=9bea5e55449dab2cff7ad3b06277cc9745417a23 "International Journal of Cancer")
The first 2 authors contributed equally to this work.
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Cancer Genetics
You have full text access to this OnlineOpen article
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma
Article first published online: 26 FEB 2002
DOI: 10.1002/ijc.10294
Copyright © 2002 Wiley-Liss, Inc.
Additional Information
How to Cite
Whiteman, D. C., Zhou, X.-P., Cummings, M. C., Pavey, S., Hayward, N. K. and Eng, C. (2002), Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer, 99: 63–67. doi: 10.1002/ijc.10294
Publication History
- Issue published online: 27 MAR 2002
- Article first published online: 26 FEB 2002
- Manuscript Accepted: 14 DEC 2001
- Manuscript Revised: 29 NOV 2001
- Manuscript Received: 22 OCT 2001
Funded by
- Queensland Cancer Fund
- National Health and Medical Research Council of Australia
- American Cancer Society. Grant Number: RPG98-211-01
- National Cancer Institute. Grant Number: P30CA16058
REFERENCES
- 1, , , et al. Localization of the gene for Cowden disease to 10q22-23. Nat Genet 1996;13: 114–6.
- 2, , , et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16: 64–7.
- 3, , , et al. Role of MMAC1 mutations in early onset breast cancer: causative in association with Cowden's syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1997;61: 1036–43.
- 4, , , et al. Mutation spectrum and genotype–phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7: 507–15.
- 5, , , et al. PTEN mutation spectrum and genotype–phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8: 1461–72.
- 6, , , et al. Germline and germline mosaic mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arterio-venous malformations and lipomatosis. Hum Mol Genet 2000;9: 765–8.
- 7, , , et al. Association of germline mutation in the PTEN tumour suppressor gene and a subset of Proteus and Proteus-like syndromes. Lancet 2001;358: 210–1.
- 8, , , et al. Expression of PTEN protein in human embryonic development. Hum Mol Genet 2000;9: 1633–9.
- 9, . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger phosphoinositol 3,4,5-triphosphate. J Biol Chem 1998;273; 13375–8.
- 10, , , et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95: 1–20.
- 11, , . The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58: 5002–8.
- 12, . PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998;95: 15406–11.
- 13, , , et al. PTEN is inversely correlated with the cell survival factor PKB/Akt and is inactivated by diverse mechanisms in haematologic malignancies. Hum Mol Genet 1999;8: 185–93.
- 14, , , et al. PTEN suppresses breast cancer cell growth by phosphatase function-dependent G1 arrest followed by apoptosis. Cancer Res 1999;59: 5808–14.
- 15, , . PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum Mol Genet 2001;10: 599–604.
- 16, , . PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways. Hum Mol Genet 2001;10: 237–42.
- 17, , , et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet 2001;10: 251–8.
- 18, , , et al. Possible involvement of the chromosome region 10q24-26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 1988;30: 313–7.
- 19, , , et al. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol 1986;86: 295–302.
- 20, , . Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988;80: 1159–64.
- 21
- 22, . 2001. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68: 410–9.
- 23, , , et al. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994;54: 3111–4.
- 24, , , et al. Mutations of the CDKN2/p16Ink4A gene in Australian melanoma kindreds. Hum Mol Genet 1995;4: 1845–52.
- 25, , , et al. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 1993;8: 178–84.Direct Link:
- 26, , , et al. 10q deletions in metastatic cutaneous melanoma. Cancer Genet Cytogenet 1998;100: 68–71.
- 27, , , et al. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res 1999;59: 3596–601.
- 28, , , et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57: 5221–5.
- 29, , , et al. Identification of PTEN/MMAC1 mutations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16: 3397–402.
- 30, , , et al. The PTEN tumour suppressor gene and malignant melanoma. Melanoma Res 1998;8: 300–2.
- 31, , , et al. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16: 3397–402.
- 32, , , et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000;114: 277–80.
- 33, , , et al. Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet 2000;37: 653–7.
- 34, , , et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000;436: 487–93.
- 35, , . PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet 2001;125: 21–6.
- 36, , , et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000;157: 1123–8.
- 37, , . p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998;77: 843–8.Direct Link:
- 38, , , et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155: 1253–60.
- 39, , , et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92: 924–31.
- 40, , , et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000;157: 1097–103.
- 41, , , et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000;156: 1693–700.
- 42, , , et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158: 2097–106.
- 43, , , et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993;129: 739–43.
- 44, , , et al. Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 1995;5: 387–92.
- 45, , , et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275: 1943–7.
- 46, , , et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000;85: 2334–8.
- 47, , , et al. Heterogeneous lack of expression of tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer 2001;37: 114–21.
- 48, . The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001;276: 993–8.
- 49, , , et al. Regulation of PTEN transcription by p53. Mol Cells 2001;8: 317–25.
- 50, , , et al. Allelic loss of 10q22-23, the PTEN tumour suppressor gene locus, in Barrett-associated esophageal adenocarcinoma. Br J Cancer 2001;84: 748–53.
- 51, , , et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61: 4311–4.